Stock Track | NeoGenomics Soars 5% Pre-Market as Q4 Earnings Beat Estimates Despite Revenue Miss

Stock Track

Feb 18, 2025

Shares of NeoGenomics (NASDAQ: NEO) surged 5.06% in pre-market trading on Tuesday, following the company's fourth-quarter earnings release that topped profit estimates but fell short on revenue.

NeoGenomics reported quarterly earnings of $0.04 per share for Q4 2024, beating the consensus analyst estimate of $0.03 per share by 33.3%. However, quarterly sales of $172 million missed analysts' expectations of $173.18 million by 0.68%. The revenue figure still represented a 10.6% increase from the same period a year ago.

While the mixed results garnered a positive initial reaction from investors, analysts cautioned that the revenue miss could temper enthusiasm going forward. "The earnings beat is encouraging, but NeoGenomics will need to demonstrate stronger sales growth to sustain momentum in the stock," said one Wall Street analyst. "Overall, the Q4 numbers give reasons for both optimism and caution on the company's prospects."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1119315698"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119315698\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119315698?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-18 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119315698","market":"us","top_or_hot":-1,"title":"Stock Track | NeoGenomics Soars 5% Pre-Market as Q4 Earnings Beat Estimates Despite Revenue Miss","media":"Stock Track","content":"<p>Shares of NeoGenomics (NASDAQ: NEO) surged 5.06% in pre-market trading on Tuesday, following the company's fourth-quarter earnings release that topped profit estimates but fell short on revenue.</p>\n\n<p>NeoGenomics reported quarterly earnings of $0.04 per share for Q4 2024, beating the consensus analyst estimate of $0.03 per share by 33.3%. However, quarterly sales of $172 million missed analysts' expectations of $173.18 million by 0.68%. The revenue figure still represented a 10.6% increase from the same period a year ago.</p>\n\n<p>While the mixed results garnered a positive initial reaction from investors, analysts cautioned that the revenue miss could temper enthusiasm going forward. \"The earnings beat is encouraging, but NeoGenomics will need to demonstrate stronger sales growth to sustain momentum in the stock,\" said one Wall Street analyst. \"Overall, the Q4 numbers give reasons for both optimism and caution on the company's prospects.\"</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | NeoGenomics Soars 5% Pre-Market as Q4 Earnings Beat Estimates Despite Revenue Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | NeoGenomics Soars 5% Pre-Market as Q4 Earnings Beat Estimates Despite Revenue Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-18 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of NeoGenomics (NASDAQ: NEO) surged 5.06% in pre-market trading on Tuesday, following the company's fourth-quarter earnings release that topped profit estimates but fell short on revenue.</p>\n\n<p>NeoGenomics reported quarterly earnings of $0.04 per share for Q4 2024, beating the consensus analyst estimate of $0.03 per share by 33.3%. However, quarterly sales of $172 million missed analysts' expectations of $173.18 million by 0.68%. The revenue figure still represented a 10.6% increase from the same period a year ago.</p>\n\n<p>While the mixed results garnered a positive initial reaction from investors, analysts cautioned that the revenue miss could temper enthusiasm going forward. \"The earnings beat is encouraging, but NeoGenomics will need to demonstrate stronger sales growth to sustain momentum in the stock,\" said one Wall Street analyst. \"Overall, the Q4 numbers give reasons for both optimism and caution on the company's prospects.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEO","symbol_name":"NeoGenomics","start_time":0,"source_url":"","article_id":"1119315698","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119315698","pubTimestamp":1739880622,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of NeoGenomics  surged 5.06% in pre-market trading on Tuesday, following the company's fourth-quarter earnings release that topped profit estimates but fell short on revenue.NeoGenomics reported quarterly earnings of $0.04 per share for Q4 2024, beating the consensus analyst estimate of $0.03 per share by 33.3%. However, quarterly sales of $172 million missed analysts' expectations of $173.18 million by 0.68%. The revenue figure still represented a 10.6% increase from the same period a ye","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEO":"NeoGenomics"},"translate_title":"尽管营收未达预期，但第四季度盈利仍超出预期，股票赛道NeoGenomics盘前飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEO":1},"content_text":"Shares of NeoGenomics (NASDAQ: NEO) surged 5.06% in pre-market trading on Tuesday, following the company's fourth-quarter earnings release that topped profit estimates but fell short on revenue.\nNeoGenomics reported quarterly earnings of $0.04 per share for Q4 2024, beating the consensus analyst estimate of $0.03 per share by 33.3%. However, quarterly sales of $172 million missed analysts' expectations of $173.18 million by 0.68%. The revenue figure still represented a 10.6% increase from the same period a year ago.\nWhile the mixed results garnered a positive initial reaction from investors, analysts cautioned that the revenue miss could temper enthusiasm going forward. \"The earnings beat is encouraging, but NeoGenomics will need to demonstrate stronger sales growth to sustain momentum in the stock,\" said one Wall Street analyst. \"Overall, the Q4 numbers give reasons for both optimism and caution on the company's prospects.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}